Aditxt (NASDAQ:ADTX) Major Shareholder Financial Lp Hrt Sells 5,120,480 Shares

Aditxt, Inc. (NASDAQ:ADTX) major shareholder Financial Lp Hrt sold 5,120,480 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $0.02, for a total transaction of $102,409.60. Following the completion of the transaction, the insider directly owned 2,406,438 shares of the company’s stock, valued at $48,128.76. This trade represents a 68.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, June 18th, Financial Lp Hrt acquired 7,340,178 shares of Aditxt stock. The stock was bought at an average price of $0.01 per share, for a total transaction of $73,401.78.
• On Tuesday, June 16th, Financial Lp Hrt sold 3,132,480 shares of Aditxt stock. The stock was sold at an average price of $0.01, for a total value of $31,324.80.
• On Friday, June 12th, Financial Lp Hrt purchased 4,252,767 shares of Aditxt stock. The stock was bought at an average price of $0.02 per share, for a total transaction of $85,055.34.
• On Friday, June 5th, Financial Lp Hrt sold 735,462 shares of Aditxt stock. The stock was sold at an average price of $0.06, for a total value of $44,127.72.
• On Thursday, June 4th, Financial Lp Hrt bought 843,622 shares of Aditxt stock. The stock was purchased at an average price of $0.08 per share, for a total transaction of $67,489.76.
• On Friday, April 24th, Financial Lp Hrt sold 1,089 shares of Aditxt stock. The stock was sold at an average price of $7.56, for a total transaction of $8,232.84.
• On Thursday, April 23rd, Financial Lp Hrt sold 141 shares of Aditxt stock. The shares were sold at an average price of $7.83, for a total transaction of $1,104.03.
• On Tuesday, April 21st, Financial Lp Hrt acquired 2,700 shares of Aditxt stock. The stock was acquired at an average price of $8.91 per share, with a total value of $24,057.00.
• On Wednesday, April 22nd, Financial Lp Hrt sold 443 shares of Aditxt stock. The stock was sold at an average price of $8.10, for a total transaction of $3,588.30.

Aditxt Price Performance

Shares of ADTX stock traded down $0.03 during trading hours on Wednesday, reaching $0.01. 4,650,711,153 shares of the company were exchanged, compared to its average volume of 124,214,039. Aditxt, Inc. has a fifty-two week low of $0.00 and a fifty-two week high of $53,451.08. The stock’s fifty day moving average is $3.16 and its two-hundred day moving average is $113.78. The company has a market cap of $7,929.40, a price-to-earnings ratio of -0.00 and a beta of 0.84.

Aditxt (NASDAQ:ADTX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $315,563.31 EPS for the quarter. Aditxt had a negative return on equity of 374.60% and a negative net margin of 360,152.50%.

Analysts Set New Price Targets

A number of research firms recently weighed in on ADTX. Wall Street Zen raised shares of Aditxt to a “sell” rating in a research note on Saturday, May 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aditxt in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

About Aditxt

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.